Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment

Treatment advances for multiple myeloma (MM) that have prolonged survival emphasise the importance of measuring patients' health-related quality of life (HRQoL) in clinical studies. HRQoL/functioning and symptoms of patients with relapsed/refractory MM (RRMM) receiving second- or third-line len...

Descripción completa

Detalles Bibliográficos
Autores principales: Leleu, X, Kyriakou, C, Vande Broek, I, Murphy, P, Bacon, P, Lewis, P, Gilet, H, Arnould, B, Petrucci, M T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380904/
https://www.ncbi.nlm.nih.gov/pubmed/28304402
http://dx.doi.org/10.1038/bcj.2017.20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380904/
https://www.ncbi.nlm.nih.gov/pubmed/28304402
http://dx.doi.org/10.1038/bcj.2017.20

Ejemplares similares